Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Covid-19 - Nigeria Approves Booster Doses for Enhanced Protection

12/04/2021 | 09:06am EST

The Nigerian government has said it will begin the administration of the COVID-19 booster dose for eligible Nigerians from December 10, across all states of the federation.

A statement released by the National Primary Health Care Development Agency (NPHCDA) on Friday evening noted that the booster doses will only be administered on Nigerians who have completed the two doses of Astrazeneca, Moderna or Pfizer Bio-N-Tech or one dose of Johnson and Johnson vaccines.

The executive director, NPHCDA, Faisal Shuaib, noted in the statement that the booster dose is strictly for persons 18 years and above.

According to Mr Shuaib, a COVID-19 booster dose gives greater protection against the virus. He urged all Nigerians to take advantage of the opportunity offered by the government.

He added that Nigerians are eligible for the booster dose if they have received the second dose of AstraZeneca, Moderna or Pfizer Bio-N-Tech within a time interval of six months or more, while two months for Johnson and Johnson vaccine.

"Consequent upon the above, eligible Nigerians are advised to visit the nearest health facility or mass vaccination site for their booster doses as from the 10th of December, 2021 across all states of the federation," the official said.

Vaccination goal

Before the discovery of Omicron variant, which has heightened concerns on how to curb the spread of COVID-19, Nigeria had set a goal of vaccinating 40 per cent of its over 200 million population before the end of 2021, and 70 per cent by the end of 2022.

But as of November 8, 2021, the NPHCDA said it has vaccinated 5,770,899 eligible persons with the first dose of the COVID-19 vaccination while 3,146,885 have taken the second dose.

The director, planning research and statistics, NPHCDA, Abdullahi Garba, disclosed that these figures were achieved in the 36 states and the FCT.

He noted that there were over eight million doses of vaccines in the country at the moment, but the country was still expecting more doses.

According to the latest Reuters COVID-19 tracker, Nigeria has administered about 10.1 million doses of COVID-19 vaccines so far.

Nigeria COVID-19 Status

Since the pandemic began in 2020, Nigeria has recorded 214,317 infections and 2,978 coronavirus fatalities across the 36 states of the federation and the Federal Capital Territory (FCT).

With over 3.5 million samples tested, Nigeria has successfully treated and discharged 207,370 patients while the latest data from NCDC also showed that about 3,969 people are still down with the disease.

Copyright Premium Times. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.11% 8744 Delayed Quote.0.85%
JOHNSON & JOHNSON -0.23% 164.87 Delayed Quote.-3.40%
MODERNA, INC. -4.45% 160.07 Delayed Quote.-36.98%
All news about ASTRAZENECA PLC
01/21Investor's Net Asset Value Jumps 41% in 2021 As Low Interest Rate Environment Uplifts R..
MT
01/20ASTRAZENECA : Deutsche Bank reaffirms its Buy rating
MD
01/20EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
RE
01/20EMA : In january 2022, prac concluded that transverse myelitis should be added to the prod..
RE
01/19India's expert panel advises full approval for Covishield, Covaxin
RE
01/19ASTRAZENECA : JP Morgan reiterates its Buy rating
MD
01/19AstraZeneca PLC Announces Positive Results from the TOPAZ-1 Phase III Trial
CI
01/19Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tr..
AQ
01/19AstraZeneca Says Liver Cancer Combination Therapy Improved Overall Survival in Late-Sta..
MT
01/19AstraZeneca Says Imfinzi Combination Shows Unprecedented Liver-Cancer Survival Rate
DJ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 096 M - -
Net income 2021 2 714 M - -
Net Debt 2021 24 816 M - -
P/E ratio 2021 57,3x
Yield 2021 2,37%
Capitalization 184 B 184 B -
EV / Sales 2021 5,78x
EV / Sales 2022 4,73x
Nbr of Employees 76 100
Free-Float -
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 118,62 $
Average target price 138,70 $
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC0.85%183 867
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356